Chong Qin

Qingdao, 266003, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications

Structure-Guided Discovery of Potent, Selective, and Orally Bioavailable Werner Syndrome RecQ Helicase Inhibitors for the Treatment of Microsatellite Instability-High Tumors.

Structure-Guided Discovery of Potent, Selective, and Orally Bioavailable Werner Syndrome RecQ Helicase Inhibitors for the Treatment of Microsatellite Instability-High Tumors.

Journal: Journal of medicinal chemistry
Published: June 03, 2026

Discovery of an Androgen Receptor Degrader Featuring a Pyridazinyl Glutarimide CRBN-Binding Motif for Transdermal Treatment of Androgenetic Alopecia.

Discovery of an Androgen Receptor Degrader Featuring a Pyridazinyl Glutarimide CRBN-Binding Motif for Transdermal Treatment of Androgenetic Alopecia.

Journal: Journal of medicinal chemistry
Published: May 29, 2026

ZJK-807: A Selective PROTAC Degrader of KRASG12D Overcoming Resistance in Pancreatic Cancer.

ZJK-807: A Selective PROTAC Degrader of KRASG12D Overcoming Resistance in Pancreatic Cancer.

Journal: Journal of medicinal chemistry
Published: September 25, 2025

Catalytic endo-stereoselective [2+2] cycloaddition of norbornadienes with internal alkynes.

Catalytic endo-stereoselective [2+2] cycloaddition of norbornadienes with internal alkynes.

Journal: Nature chemistry
Published: September 24, 2025

Design, synthesis, and biological evaluation of novel HDAC3 PROTACs for combined therapy with Venetoclax in acute myeloid leukemia.

Design, synthesis, and biological evaluation of novel HDAC3 PROTACs for combined therapy with Venetoclax in acute myeloid leukemia.

Journal: Bioorganic chemistry
Published: September 03, 2025

Discovery of LYA914, An Orally Bioavailable PROTAC Degrader Targeting the DNA Binding Domain of the Androgen Receptor for the Treatment of CRPC.

Discovery of LYA914, An Orally Bioavailable PROTAC Degrader Targeting the DNA Binding Domain of the Androgen Receptor for the Treatment of CRPC.

Journal: Journal of medicinal chemistry
Published: July 28, 2025

MolGlueDB: an online database of molecular glues.

MolGlueDB: an online database of molecular glues.

Journal: Nucleic acids research
Published: June 07, 2025

Rational Design of Dual Degraders by Incorporating Molecular Glue Structural Features into PROTAC Degraders.

Rational Design of Dual Degraders by Incorporating Molecular Glue Structural Features into PROTAC Degraders.

Journal: Journal of medicinal chemistry
Published: May 09, 2025

PSMA-Guided PROTAC Degraders for Tumor-Specific Protein Degradation in Prostate Cancer.

PSMA-Guided PROTAC Degraders for Tumor-Specific Protein Degradation in Prostate Cancer.

Journal: Journal of medicinal chemistry
Published: May 02, 2025

Discovery of a Highly Potent PROTAC Degrader of p300/CBP Proteins for the Treatment of Enzalutamide-Resistant Prostate Cancer.

Discovery of a Highly Potent PROTAC Degrader of p300/CBP Proteins for the Treatment of Enzalutamide-Resistant Prostate Cancer.

Journal: Journal of medicinal chemistry
Published: September 30, 2024

Marine Cytotoxin Santacruzamate A Derivatives as Potent HDAC1-3 Inhibitors and Their Synergistic Anti-Leukemia Effects with Venetoclax.

Marine Cytotoxin Santacruzamate A Derivatives as Potent HDAC1-3 Inhibitors and Their Synergistic Anti-Leukemia Effects with Venetoclax.

Journal: Marine drugs
Published: April 29, 2024

A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRASG12C Inhibitor.

A Potent SOS1 PROTAC Degrader with Synergistic Efficacy in Combination with KRASG12C Inhibitor.

Journal: Journal of medicinal chemistry
Published: February 05, 2024
Showing 1-12 of 30

Last Updated: 09/26/2026